Is Tenax Therapeutics Stock a Good Investment?
Tenax Therapeutics Investment Advice | TENX |
- Examine Tenax Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Tenax Therapeutics' leadership team and their track record. Good management can help Tenax Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Tenax Therapeutics' business and its evolving consumer preferences.
- Compare Tenax Therapeutics' performance and market position to its competitors. Analyze how Tenax Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Tenax Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Tenax Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Tenax Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Tenax Therapeutics is a good investment.
Sell | Buy |
Hold
Market Performance | Solid | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Tenax Therapeutics Stock
Researching Tenax Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 48.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.21. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tenax Therapeutics recorded a loss per share of 13.05. The entity last dividend was issued on the 26th of February 2018. The firm had 1:80 split on the 3rd of January 2024.
To determine if Tenax Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tenax Therapeutics' research are outlined below:
| Tenax Therapeutics appears to be risky and price may revert if volatility continues | |
| Tenax Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.71 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tenax Therapeutics currently holds about 7.23 M in cash with (5.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29. | |
| Tenax Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Will Tenax Therapeutics Spend Its Cash Wisely |
Tenax Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tenax Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tenax Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Tenax Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Tenax Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-13 | 2023-09-30 | -0.09 | -0.08 | 0.01 | 11 | ||
2022-05-16 | 2022-03-31 | -0.09 | -0.11 | -0.02 | 22 | ||
2023-08-14 | 2023-06-30 | -0.1 | -0.05 | 0.05 | 50 | ||
2023-05-15 | 2023-03-31 | -0.37 | -0.15 | 0.22 | 59 | ||
2022-08-11 | 2022-06-30 | -1.8 | -2.2 | -0.4 | 22 | ||
2021-11-15 | 2021-09-30 | -2.6 | -3.0 | -0.4 | 15 | ||
2023-03-31 | 2022-12-31 | -2.28 | -1.73 | 0.55 | 24 | ||
2021-08-16 | 2021-06-30 | -2.6 | -2.0 | 0.6 | 23 |
Know Tenax Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tenax Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tenax Therapeutics backward and forwards among themselves. Tenax Therapeutics' institutional investor refers to the entity that pools money to purchase Tenax Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 18.4 K | Tower Research Capital Llc | 2024-09-30 | 1.7 K | Ubs Group Ag | 2024-09-30 | 688 | Blackrock Inc | 2024-06-30 | 300 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 260 | Bank Of America Corp | 2024-09-30 | 28.0 | Hanson Mcclain Inc | 2024-09-30 | 1.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Fmr Inc | 2024-09-30 | 0.0 | Bvf Inc | 2024-09-30 | 339.5 K | Vivo Capital, Llc | 2024-09-30 | 208.3 K |
Tenax Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.24 M.Market Cap |
|
Tenax Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.66) | (0.69) | |
| Return On Capital Employed | (1.02) | (0.97) | |
| Return On Assets | (0.66) | (0.69) | |
| Return On Equity | (0.95) | (0.90) |
Determining Tenax Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Tenax Therapeutics is a good buy. For example, gross profit margin measures Tenax Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tenax Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Tenax Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tenax Therapeutics. Check Tenax Therapeutics' Beneish M Score to see the likelihood of Tenax Therapeutics' management manipulating its earnings.
Evaluate Tenax Therapeutics' management efficiency
Tenax Therapeutics has return on total asset (ROA) of (0.6609) % which means that it has lost $0.6609 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1379) %, meaning that it created substantial loss on money invested by shareholders. Tenax Therapeutics' management efficiency ratios could be used to measure how well Tenax Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.69 in 2024. Return On Capital Employed is likely to rise to -0.97 in 2024. At this time, Tenax Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 2 M in 2024, whereas Non Current Assets Total are likely to drop 1,061 in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 32.65 | 31.02 | |
| Tangible Book Value Per Share | 32.65 | 31.02 | |
| Enterprise Value Over EBITDA | 0.47 | 0.49 | |
| Price Book Value Ratio | 0.67 | 0.71 | |
| Enterprise Value Multiple | 0.47 | 0.49 | |
| Price Fair Value | 0.67 | 0.71 | |
| Enterprise Value | 1.8 M | 1.6 M |
Leadership effectiveness at Tenax Therapeutics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 2.154 |
Basic technical analysis of Tenax Stock
As of the 10th of December, Tenax Therapeutics has the Semi Deviation of 2.6, risk adjusted performance of 0.1673, and Coefficient Of Variation of 453.39. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tenax Therapeutics, as well as the relationship between them.Tenax Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tenax Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tenax Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tenax Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tenax Therapeutics' Outstanding Corporate Bonds
Tenax Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tenax Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tenax bonds can be classified according to their maturity, which is the date when Tenax Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Pactiv 8375 percent Corp BondUS880394AE11 | View | |
| Pactiv 795 percent Corp BondUS880394AB71 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| THC 5125 01 NOV 27 Corp BondUS88033GDB32 | View | |
| THC 6125 01 OCT 28 Corp BondUS88033GDK31 | View | |
| THC 425 01 JUN 29 Corp BondUS88033GDM96 | View |
Understand Tenax Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Tenax Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1673 | |||
| Market Risk Adjusted Performance | 0.9256 | |||
| Mean Deviation | 2.74 | |||
| Semi Deviation | 2.6 | |||
| Downside Deviation | 3.03 | |||
| Coefficient Of Variation | 453.39 | |||
| Standard Deviation | 3.6 | |||
| Variance | 12.99 | |||
| Information Ratio | 0.186 | |||
| Jensen Alpha | 0.6869 | |||
| Total Risk Alpha | 0.214 | |||
| Sortino Ratio | 0.221 | |||
| Treynor Ratio | 0.9156 | |||
| Maximum Drawdown | 18.97 | |||
| Value At Risk | (5.75) | |||
| Potential Upside | 6.72 | |||
| Downside Variance | 9.21 | |||
| Semi Variance | 6.74 | |||
| Expected Short fall | (3.27) | |||
| Skewness | 0.5613 | |||
| Kurtosis | 1.38 |
| Risk Adjusted Performance | 0.1673 | |||
| Market Risk Adjusted Performance | 0.9256 | |||
| Mean Deviation | 2.74 | |||
| Semi Deviation | 2.6 | |||
| Downside Deviation | 3.03 | |||
| Coefficient Of Variation | 453.39 | |||
| Standard Deviation | 3.6 | |||
| Variance | 12.99 | |||
| Information Ratio | 0.186 | |||
| Jensen Alpha | 0.6869 | |||
| Total Risk Alpha | 0.214 | |||
| Sortino Ratio | 0.221 | |||
| Treynor Ratio | 0.9156 | |||
| Maximum Drawdown | 18.97 | |||
| Value At Risk | (5.75) | |||
| Potential Upside | 6.72 | |||
| Downside Variance | 9.21 | |||
| Semi Variance | 6.74 | |||
| Expected Short fall | (3.27) | |||
| Skewness | 0.5613 | |||
| Kurtosis | 1.38 |
Consider Tenax Therapeutics' intraday indicators
Tenax Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tenax Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Tenax Therapeutics Corporate Filings
F3 | 6th of December 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 5th of December 2024 Other Reports | ViewVerify | |
8K | 4th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 26th of November 2024 Other Reports | ViewVerify |
Tenax Stock media impact
Far too much social signal, news, headlines, and media speculation about Tenax Therapeutics that are available to investors today. That information is available publicly through Tenax media outlets and privately through word of mouth or via Tenax internal channels. However, regardless of the origin, that massive amount of Tenax data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tenax Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tenax Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tenax Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tenax Therapeutics alpha.
Tenax Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Tenax Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tenax Therapeutics Corporate Management
| Doug Randall | Executive VP of Commercial and Bus. Operations | Profile | |
| Eliot CPA | Interim Officer | Profile | |
| Nancy Hecox | Gen Affairs | Profile | |
| Esq CPA | Interim Officer | Profile |
Additional Tools for Tenax Stock Analysis
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.